Aptamer Group to host webinar and Q&A session for investors

Aptamer Group plc (LON: APTA), the developer of novel Optimer^® binders to enable innovation in the life sciences industry, has announced that Dr Arron Tolley, Chief Executive Officer and Dr David Bunka, Chief Scientific Officer will be hosting a webinar on Thursday, 12 December 2024 at 6.00 pm (GMT).

The webinar will provide investors with a valuable opportunity to interact with Aptamer Group and gain insights into recent announcements.

There will be a Q&A session for investors after the presentation and questions can be submitted pre-event as part of the registration process.

You can register for the event by using the following link:

https://www.turnerpope.com/register/

We are delighted to announce that the webinar will be chaired by experienced news and corporate events presenter Katie Pilbeam (www.katiepilbeam.com) and hosted by the Company’s broker, Turner Pope Investments.

Share on:

You might also enjoy reading Aptamer Group raises £2m to fund growth

Written by: Amilia Stone

Find more news, interviews, share price & company profile here for:

Latest Company News

Aptamer Group extends Unilever collaboration for deodorant Optimers

Aptamer Group has secured additional paid work from Unilever under their existing collaboration, advancing Optimers as deodorant actives with expanded stability testing ahead of on‑person trials.

Aptamer Group raises £2.0 million in share placing

Aptamer has raised £2.0 million (before expenses) by placing 666,666,666 new ordinary shares at 0.3 p each, representing 25.1 per cent of its enlarged issued share capital. The proceeds will accelerate commercialisation of the Optimer® platform, support in-house manufacturing, launch new biomarker services and develop AI-driven aptamer discovery.

Aptamer Group raises £2m to fund growth

Aptamer Group plc has raised £2.0 million (before expenses) via a placing of new ordinary shares at 0.3p per share, representing a 21.1% discount.

Aptamer advances liver fibrosis therapy with targeted gene delivery

Aptamer Group has identified a novel target using its Optimer® platform to deliver gene therapy directly to liver scarring cells.

Aptamer signs licensing deal for Optimer®-Fc diagnostic reagent

Aptamer Group has entered a funded development and licensing agreement with a global life sciences company to create an Optimer®-Fc reagent for diagnostic kits. The deal includes royalties on future sales, supporting Aptamer’s recurring revenue growth.

Aptamer expands odour control collaboration with Unilever

Aptamer Group plc has partnered with Unilever for a second Optimer program, aiming to innovate body odour control solutions in the personal care market.